Chembio Diagnostics (NASDAQ:CEMI) Releases Quarterly Earnings Results, Misses Estimates By $0.08 EPS

Chembio Diagnostics (NASDAQ:CEMI – Get Rating) announced its quarterly earnings data on Thursday. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.08), MarketWatch Earnings reports. Chembio Diagnostics had a negative net margin of 70.90% and a negative return on equity of 89.24%. During the same quarter in the previous year, the company posted ($0.22) EPS.

CEMI stock traded down $0.11 on Friday, hitting $0.56. 270,626 shares of the company were exchanged, compared to its average volume of 194,877. Chembio Diagnostics has a twelve month low of $0.53 and a twelve month high of $7.34. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.59 and a quick ratio of 2.74. The business’s fifty day moving average is $0.75 and its two-hundred day moving average is $1.25. The stock has a market capitalization of $16.86 million, a price-to-earnings ratio of -0.38 and a beta of 1.73.

Several equities analysts recently issued reports on CEMI shares. Zacks Investment Research downgraded shares of Chembio Diagnostics from a “hold” rating to a “sell” rating in a research note on Wednesday, March 9th. Colliers Securities reissued a “neutral” rating on shares of Chembio Diagnostics in a research note on Tuesday, March 22nd. Finally, StockNews.com assumed coverage on shares of Chembio Diagnostics in a research note on Thursday. They set a “sell” rating on the stock.

A number of hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. increased its position in Chembio Diagnostics by 2,264.1% during the fourth quarter. JPMorgan Chase & Co. now owns 33,452 shares of the company’s stock worth $38,000 after purchasing an additional 32,037 shares during the last quarter. Geode Capital Management LLC increased its position in Chembio Diagnostics by 40.4% during the third quarter. Geode Capital Management LLC now owns 203,070 shares of the company’s stock worth $507,000 after purchasing an additional 58,448 shares during the last quarter. Morgan Stanley increased its position in shares of Chembio Diagnostics by 235.8% in the third quarter. Morgan Stanley now owns 122,123 shares of the company’s stock worth $305,000 after acquiring an additional 85,756 shares in the last quarter. Goldman Sachs Group Inc. acquired a new stake in shares of Chembio Diagnostics in the fourth quarter worth $105,000. Finally, Virtu Financial LLC increased its position in shares of Chembio Diagnostics by 506.7% in the fourth quarter. Virtu Financial LLC now owns 119,238 shares of the company’s stock worth $136,000 after acquiring an additional 99,585 shares in the last quarter. 13.27% of the stock is owned by hedge funds and other institutional investors.

About Chembio Diagnostics (Get Rating)

Chembio Diagnostics, Inc, together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, lassa, marburg, leptospirosis, rickettsia, and Burkholderia diseases.

Recommended Stories